ArticleNeurology and therapy2025

Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation.

Masaaki Yoshikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.